Drug Profile
Research programme: autoimmune disease therapies - Casebia therapeutics/Seattle Children's Research Institute
Alternative Names: CRISPR/Cas9 gene edited regulatory T cells - Casebia therapeutics/Seattle Children's Research InstituteLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Casebia Therapeutics; Seattle Childrens Research Institute
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 07 Dec 2019 Pharmacodynamics data from a preclinical study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
- 27 Sep 2017 Casebia Therapeutics enters into an license and collaboration agreement with Seattle Children’s Research Institute for the development of engineered regulatory T cells